Skip to main content
Funded Studies

Mary Maral Mouradian, MD

William Dow Lovett Professor of Neurology; Director of the RWJMS Institute for Neurological Therapeutics; and Vice Chancellor for Faculty Development, Rutgers Biomedical and Health Sciences - Robert Wood Johnson Medical School

Location: Piscataway, NJ United States

M. Maral Mouradian is an internationally recognized physician-scientist trained in both clinical neuropharmacology at NINDS and in molecular biology under the tutelage of the Nobel Laureate Marshall Nirenberg at NHLBI. Before assuming her current posts at Rutgers, she directed the Genetic Pharmacology group of NINDS conducting translational research in neurodegenerative disorders. Her contributions to Parkinson’s disease span seminal research providing the rationale for continuous dopaminergic drug delivery to mitigate the motor complications of L-Dopa, elucidation of molecular pathogenetic mechanisms of neurodegeneration, and identification of new therapeutic targets and agents. To date, she has authored over 200 scholarly publications. Dr. Mouradian is the Editor-in-Chief of the journal Neurotherapeutics and directs the American Parkinson Disease Association (APDA) Center for Advanced Research at RWJMS. She serves on the Board of Directors of the American Neurological Association and on the Scientific Advisory Board of the APDA. Among her honors are the NIH Award of Merit and election to the Association of American Physicians.


Associated Grants

  • RNA Targeting Small Molecules as Therapeutics for Parkinson's

    2021


  • Transglutaminase 2 Inhibitors as a Disease-Modifying Treatment for Parkinson's Disease

    2019


  • Validation of a Protein, Transglutaminase 2, as a Way to Reduce Alpha-synuclein Clumping and Toxicity in Parkinson's Disease

    2016


  • Development of a Treatment for Dyskinesia Targeting Opioid Receptors

    2011


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.